{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:16:09Z","timestamp":1784970969508,"version":"3.55.0"},"reference-count":65,"publisher":"Cambridge University Press (CUP)","issue":"9","license":[{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychol. Med."],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec id=\"S0033291716000398_sec_a1\"><jats:title>Background<\/jats:title><jats:p>Dysfunction of neuroplasticity due to <jats:italic>N<\/jats:italic>-methyl-<jats:sc>d<\/jats:sc>-aspartate (NMDA) receptor hypofunction may be a causal factor for memory and executive dysfunctioning in schizophrenia. Deregulation of NMDA transmission in the prefrontal cortex may also explain negative and positive symptoms. Clozapine augmentation with memantine targets altered NMDA receptor-mediated neurotransmission in schizophrenia and showed substantial beneficial effects on several symptom domains in a small proof-of-concept study. We evaluate effects of memantine add-on treatment to clozapine for memory and executive function, and negative and positive symptoms in schizophrenia.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291716000398_sec_a2\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>Clozapine-treated patients with refractory schizophrenia were randomly assigned to 12 weeks of double-blind adjunctive treatment with memantine (<jats:italic>n<\/jats:italic> = 26) or placebo (<jats:italic>n<\/jats:italic> = 26). Crossover occurred after a 2-week placebo wash-out period. Primary endpoints were change from baseline to 12 weeks treatment and 14 weeks to 26 weeks treatment on memory and executive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB), Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression Severity Scale (CGI-S). Side effects were assessed using the Liverpool University Neuroleptic Side-Effect Rating Scale.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291716000398_sec_a3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>When compared with placebo, memantine improved a composite memory score comprising verbal recognition memory and paired associates learning task scores on the CANTAB (effect size = 0.30) and PANSS negative subscale score (effect size = 0.29). Side effects were mild and transient.<\/jats:p><\/jats:sec><jats:sec id=\"S0033291716000398_sec_a4\" sec-type=\"conclusion\"><jats:title>Conclusions<\/jats:title><jats:p>In patients with clozapine-treated refractory schizophrenia, memantine addition significantly improved verbal and visual memory and negative symptoms without serious adverse effects. These results justify further investigations on long-term memantine augmentation to clozapine in treatment-resistant schizophrenia.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s0033291716000398","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T11:31:44Z","timestamp":1459942304000},"page":"1909-1921","source":"Crossref","is-referenced-by-count":66,"title":["Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study"],"prefix":"10.1017","volume":"46","author":[{"given":"S. R. T.","family":"Veerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. F. J.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"S0033291716000398_ref29","doi-asserted-by":"publisher","DOI":"10.4306\/pi.2012.9.2.166"},{"key":"S0033291716000398_ref45","first-page":"553","article-title":"Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease","volume":"5","author":"Puangthong","year":"2009","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"S0033291716000398_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"S0033291716000398_ref41","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010042"},{"key":"S0033291716000398_ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.10.043"},{"key":"S0033291716000398_ref43","volume-title":"MINI. Mini International Neuropsychiatric Interview","author":"Overbeek","year":"1999"},{"key":"S0033291716000398_ref21","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2213-07.2007"},{"key":"S0033291716000398_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(96)02870-3"},{"key":"S0033291716000398_ref15","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006288734"},{"key":"S0033291716000398_ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2012.00203"},{"key":"S0033291716000398_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1992.00530250091022"},{"key":"S0033291716000398_ref51","unstructured":"SPSS Inc. (2014). SPSS Statistics version 22.0.0. SPSS Inc.: Chicago, IL."},{"key":"S0033291716000398_ref50","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001"},{"key":"S0033291716000398_ref33","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.200"},{"key":"S0033291716000398_ref64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010025108"},{"key":"S0033291716000398_ref53","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.143701"},{"key":"S0033291716000398_ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108089816"},{"key":"S0033291716000398_ref46","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19991130)18:22<3037::AID-SIM243>3.0.CO;2-7"},{"key":"S0033291716000398_ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-014-0253-4"},{"key":"S0033291716000398_ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.2.218"},{"key":"S0033291716000398_ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831070-00003"},{"key":"S0033291716000398_ref7","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"S0033291716000398_ref19","first-page":"405","article-title":"Transcranial brain stimulation in schizophrenia: targeting cortical excitability, connectivity and plasticity","volume":"20","author":"Hasan","year":"2013","journal-title":"Current Medicinal Chemistry"},{"key":"S0033291716000398_ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-007-9089-4"},{"key":"S0033291716000398_ref24","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"American Journal of Psychiatry"},{"key":"S0033291716000398_ref35","doi-asserted-by":"publisher","DOI":"10.1002\/9781119013563"},{"key":"S0033291716000398_ref40","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110372548"},{"key":"S0033291716000398_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.01.024"},{"key":"S0033291716000398_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2006.11.004"},{"key":"S0033291716000398_ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.5.650"},{"key":"S0033291716000398_ref25","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2506-07.2007"},{"key":"S0033291716000398_ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01308.x"},{"key":"S0033291716000398_ref38","article-title":"Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive","author":"Mouchlianitis","year":"2015","journal-title":"Schizophrenia Bulletin"},{"key":"S0033291716000398_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp006"},{"key":"S0033291716000398_ref48","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342070-00001"},{"key":"S0033291716000398_ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub3"},{"key":"S0033291716000398_ref16","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31815abf34"},{"key":"S0033291716000398_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2010.01.012"},{"key":"S0033291716000398_ref18","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S0033291716000398_ref11","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291797004790"},{"key":"S0033291716000398_ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2013.00035"},{"key":"S0033291716000398_ref59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0034-1383657","article-title":"The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged","volume":"47","author":"Veerman","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"S0033291716000398_ref52","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106073126"},{"key":"S0033291716000398_ref17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"American Journal of Psychiatry"},{"key":"S0033291716000398_ref20","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"S0033291716000398_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.03.008"},{"key":"S0033291716000398_ref5","doi-asserted-by":"publisher","DOI":"10.1038\/361031a0"},{"key":"S0033291716000398_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000372"},{"key":"S0033291716000398_ref47","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31828b50a7"},{"key":"S0033291716000398_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3932(98)00036-0"},{"key":"S0033291716000398_ref54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01638.x"},{"key":"S0033291716000398_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2010.04.006"},{"key":"S0033291716000398_ref44","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-529-9_2"},{"key":"S0033291716000398_ref30","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2010.156"},{"key":"S0033291716000398_ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.11.006"},{"key":"S0033291716000398_ref57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-0034-1385930","article-title":"Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis","volume":"47","author":"Veerman","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"S0033291716000398_ref9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04935gry"},{"key":"S0033291716000398_ref27","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S0033291716000398_ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.02.009"},{"key":"S0033291716000398_ref63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"S0033291716000398_ref39","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.956082"},{"key":"S0033291716000398_ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.441"},{"key":"S0033291716000398_ref58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0034-1383656","article-title":"Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis","volume":"47","author":"Veerman","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"S0033291716000398_ref62","doi-asserted-by":"publisher","DOI":"10.1159\/000102568"},{"key":"S0033291716000398_ref61","first-page":"1122","article-title":"Pharmacodynamics and pharmacokinetics of memantine","volume":"33","author":"Wesemann","year":"1983","journal-title":"Arzniemittelforschung"}],"container-title":["Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0033291716000398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T02:18:29Z","timestamp":1555640309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0033291716000398\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0033291716000398"],"URL":"https:\/\/doi.org\/10.1017\/s0033291716000398","relation":{},"ISSN":["0033-2917","1469-8978"],"issn-type":[{"value":"0033-2917","type":"print"},{"value":"1469-8978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,6]]}}}